Brokers Offer Predictions for Belite Bio FY2026 Earnings

Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Belite Bio in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Kim forecasts that the company will post earnings per share of ($2.00) for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share.

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Belite Bio from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Belite Bio in a research note on Thursday, May 15th. Finally, Benchmark restated a "buy" rating and set a $80.00 price objective on shares of Belite Bio in a research report on Wednesday, March 26th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $96.67.

Belite Bio Stock Up 1.0%

Shares of NASDAQ:BLTE traded up $0.61 during midday trading on Wednesday, hitting $61.71. The stock had a trading volume of 26,031 shares, compared to its average volume of 47,980. The company's 50-day moving average price is $60.77 and its 200-day moving average price is $61.25. Belite Bio has a fifty-two week low of $43.70 and a fifty-two week high of $86.53. The company has a market capitalization of $1.96 billion, a P/E ratio of -55.59 and a beta of -1.44.

Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).

Institutional Trading of Belite Bio

A number of hedge funds have recently added to or reduced their stakes in BLTE. GAMMA Investing LLC lifted its stake in shares of Belite Bio by 43.3% in the 1st quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock valued at $122,000 after acquiring an additional 559 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Belite Bio in the 4th quarter worth about $155,000. XTX Topco Ltd raised its position in Belite Bio by 30.9% in the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock valued at $446,000 after purchasing an additional 1,668 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Belite Bio by 130.3% during the fourth quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company's stock valued at $924,000 after purchasing an additional 8,280 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Belite Bio by 36.4% during the fourth quarter. Bank of America Corp DE now owns 18,342 shares of the company's stock worth $1,157,000 after purchasing an additional 4,891 shares during the last quarter. Institutional investors and hedge funds own 0.53% of the company's stock.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.